ANTHERA PHARMACEUTICALS, INC. (NASDAQ:ANTH) Files An 8-K Other Events
Item 8.01 Other Events.
issued a press release announcing topline efficacy and safety
data from the Companys Phase 3 SOLUTION clinical study with
SollpuraTM in cystic fibrosis patients with exocrine
pancreatic insufficiency.
|
Exhibit No.
|
Description
|
|
|
99.1
|
Press Release dated December 27, 2016.
|
About ANTHERA PHARMACEUTICALS, INC. (NASDAQ:ANTH)
Anthera Pharmaceuticals, Inc. (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod. Sollpura is a non-porcine investigational Pancreatic Enzyme Replacement Therapy (PERT) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (EPI), often seen in patients with cystic fibrosis and other conditions. Blisibimod targets B-cell activating factor (BAFF), which has been shown to be elevated in a range of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), or lupus, Immunoglobulin A nephropathy (IgA) nephropathy, lupus nephritis and others. ANTHERA PHARMACEUTICALS, INC. (NASDAQ:ANTH) Recent Trading Information
ANTHERA PHARMACEUTICALS, INC. (NASDAQ:ANTH) closed its last trading session down -1.290 at 0.720 with 2,396,562 shares trading hands.
